Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
Jae Kyeom Sim, Juwhan Choi, Sung Yong Lee
Korean J Intern Med. 2023;38(6):787-796. Published online 2023 Nov 1 DOI: https://doi.org/10.3904/kjim.2023.345
Citations to this article as recorded by 
Perioperative immunotherapy for nonsmall cell lung cancer
Jingya Huang, Wenyuan Li, Hui Guo
Current Opinion in Oncology.2025; 37(1): 63. CrossRef
Efficacy and adverse events of immune checkpoint inhibitors: evidence from non-small cell lung cancer and gastric cancer in Korea and Japan
Mc Neil Valencia, Zeeshan Abbas, Seung Won Lee
Precision and Future Medicine.2025; 9(1): 15. CrossRef
Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials
Anping Yu, Feng Fu, Xiongying Li, Mengxin Wu, Meijian Yu, Wenxiong Zhang
Frontiers in Oncology.2024;[Epub] CrossRef
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
Evangelia Bogatsa, George Lazaridis, Chrysoula Stivanaki, Eleni Timotheadou
Cancers.2024; 16(9): 1619. CrossRef